<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

Q418/FY18 Joint Fluid Market Recap

Posted by Freddy Buntoum on 3/18/19 12:45 PM

Revenues down again, owing to intense competitive pricing pressures

Pricing pressure continued to negatively impact the US Joint Fluid market, which experienced a decline of -7.9% based on Q418 revenues according to SmartTRAK Financial Dashboard. While this market continued to see unit volume increases, ASPs experienced notable declines over the past four quarters as a result of several companies not listing ASPs to CMS, which fueled competitive pricing. Additionally, revenues were impacted by the Anthem non-coverage decision that took effect in Q118 and kept impacting suppliers over the course of the year...

Among the many topics covered in the Q418/FY18 Joint Fluid Market Recap:

Read More

Topics: OrthoBio-Joint Fluid

Q318 Joint Fluid Market Recap-Trending Downward Owing to Pricing Declines

Posted by Sharon O'Reilly on 12/5/18 9:55 AM

Pricing pressure continues to dampen the US Joint Fluid market, which experienced a double-digit decline of -9.9% according to SmartTRAK's Financial Dashboard results. While the market continues to expand in terms of the number of patients treated, ASPs have steadily eroded over the past three quarters since the Anthem non-coverage decision kicked in earlier this year. Year-to-date, the US Joint Fluid market slowed significantly, posting negative growth according to SmartTRAK estimates...

Read More

Topics: OrthoBio, OrthoBio-Joint Fluid, Q318 Market Recaps

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts